JUL 24·SEC EDGARLow
Choo Chee Kong purchased $300K of GDTC
Choo Chee Kong purchased 200,000 shares of CytoMed Therapeutics Ltd (GDTC) at $1.50 ($0.30M total) across 2 trades over 2026-07-14 to 2026-07-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$GDTC
CytoMed Therapeutics Ltd
Price · $GDTCvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $GDTC in the last 7 days.
Insider · 30dAll trades →
- Buys
- $300K 2 txs
- Sells
- — 0 txs
Choo Chee Kong2× · $300K
10b5-1 plan0%
Top stories · $GDTCMore →
JUN 15·SEC EDGAR
Choo Chee Kong purchased $129K of GDTC
Choo Chee Kong purchased 112,000 shares of CytoMed Therapeutics Ltd (GDTC) at $1.15 ($0.13M total) on 2026-05-13.
MAR 25·Intellectia AI
GDTC Forecast — Price Prediction for 2026. Should I Buy GDTC?
This article provides a detailed analysis and price prediction for CytoMed Therapeutics Ltd (GDTC) stock, indicating a "Strong Sell" recommendation based on negative technical signals, bearish moving average trends, and short-selling activity. Although GDTC experienced a slight increase recently, it has shown an overall decline over the past three years. The report suggests October as the month with the highest probability for positive returns based on seasonality, but generally advises caution due to several negative indicators.
GDTC sentiment & insider activity
Recent GDTC coverage spans financial news and insider activity.
In the last 30 days, GDTC insiders filed 2 SEC Form 4 transactions — 2 purchases ($300K) and no sales. The most active reporter was Choo Chee Kong with 2 filings.
What's driving GDTC
This is a routine insider open-market purchase with modest dollar size, offering limited incremental signal versus broader fundamentals.
Insider open-market buying is a modest bullish signal, but it is not a fundamental catalyst by itself.
The analysis indicates a strong bearish outlook for GDTC, with technical signals pointing towards a decline. The stock has shown a consistent downward trend over the past three years, and recent short-selling activity reinforces negative sentiment. Seasonality suggests October may offer some positive returns, but overall risks are high.
The news indicates a positive development for CytoMed Therapeutics, potentially supporting its stock price in the short to medium term.
CytoMed Therapeutics announced a non-dilutive investment for its subsidiary, indicating strong investor confidence and potential for strategic growth.
alphai scores every news story that mentions GDTC with an AI model for sentiment and relevance, and aggregates insider trades from CytoMed Therapeutics Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $GDTC
Score
Choo Chee Kong purchased $300K of GDTC
Choo Chee Kong purchased 200,000 shares of CytoMed Therapeutics Ltd (GDTC) at $1.50 ($0.30M total) across 2 trades over 2026-07-14 to 2026-07-20.
2 min readChoo Chee Kong purchased $129K of GDTC
Choo Chee Kong purchased 112,000 shares of CytoMed Therapeutics Ltd (GDTC) at $1.15 ($0.13M total) on 2026-05-13.
1 min readGDTC Forecast — Price Prediction for 2026. Should I Buy GDTC?
This article provides a detailed analysis and price prediction for CytoMed Therapeutics Ltd (GDTC) stock, indicating a "Strong Sell" recommendation based on negative technical signals, bearish moving average trends, and short-selling activity. Although GDTC experienced a slight increase recently, it has shown an overall decline over the past three years. The report suggests October as the month with the highest probability for positive returns based on seasonality, but generally advises caution due to several negative indicators.
4 min read
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India - CytoMed Therapeutics (NASDAQ:GDTC), TC BioPharm (Holdings) (OTC:TCBPY)
SINGAPORE, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- CytoMed Therapeutics Limited ( NASDAQ:GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based ...
3 min readCytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy - CytoMed Therapeutics (NASDAQ:GDTC)
SINGAPORE, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- CytoMed Therapeutics Limited ( NASDAQ:GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based ...
3 min readUpdate on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
SINGAPORE, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- CytoMed Therapeutics Limited ( NASDAQ: GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based ...
3 min readCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- CytoMed Therapeutics Limited ( NASDAQ: GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic ...
3 min read
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - CytoMed Therapeutics (NASDAQ:GDTC)
SINGAPORE, July 21, 2025 ( GLOBE NEWSWIRE ) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited GDTC ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to ...
2 min readUpdate On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
SINGAPORE, July 21, 2025 ( GLOBE NEWSWIRE ) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited ( NASDAQ: GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary ...
4 min read